EDMONTON, Alberta — September 5, 2012. Fedora Pharmaceuticals, Inc. announced the appointment of Thomas Parr, Ph.D. to the newly created role of Chief Scientific Officer. Dr. Parr was most recently CSO at Targanta Therapeutics, where he was instrumental in the development of oritavancin.
Tom has worked in the infectious disease space for more than two decades and has broad corporate experience in start-up, public biotechnology, and large pharmaceutical companies. This industry knowledge will be invaluable as Fedora advances its first β-lactamase inhibitor candidates through preclinical development and into clinical trials.Christopher Micetich, CEO & Founder
Dr. Parr received his Ph.D. in microbiology and infectious diseases from the University of Calgary and was a postdoctoral fellow at the University of British Columbia. During his career he worked on a broad range of marketed antibiotics across many chemical classes.
Having worked in the infectious disease industry for most of my career, I have seen both the great potential of antibiotics and the incredible damage caused by antibiotic resistance. I look forward to working with the team here at Fedora.Thomas Parr, Ph.D., Chief Scientific Officer
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
